HNO Journal Impact Factor & Information

Publisher: Springer Verlag

Journal description

Die Zeitschrift HNO berichtet über aktuelle wissenschaftliche Ergebnisse aus Klinik und Forschung. Die Herausgeber sind bemüht bei der Auswahl der Beiträge auch die Interessen des in der Praxis tätigen HNO-Arztes zu berücksichtigen. Zugleich wird in diagnostischen und therapeutischen Fragen des Fachgebietes eine kontinuierliche Fortbildung vermittelt. Über wichtige Kongresse und Symposien wird zusammenfassend in kurzen Berichten informiert. Zur Publikation eingereichte Manuskripte müssen bei Untersuchungen an Probanden oder Patienten die Erklärung enthalten daß das Versuchsprotokoll von einer Ethikkomission begutachtet wurde und somit den ethischen Standards der Deklaration von Helsinki 1964 in der jeweils gültigen Fassung (Pharm. Ind. Nr. 12/1990 sowie Bundesanzeiger Nr. 243a vom 29.12.1989) entspricht. Gleichzeitig ist die Einwilligung der Versuchsperson nach Aufklärung im Text des Manuskriptes zu fixieren. Hinweise die auf die Identität der Versuchsperson schließen lassen sind zu vermeiden. Tierversuchsprogramme müssen den Passus enthalten daß die "Principles of laboratory animal care" (NIH publication No. 86-23 revised 1985) eingehalten wurden soweit nicht zusätzlich besondere nationale Regelungen zu beachten sind (für die Bundesrepublik Deutschland ist dies das Tierschutzgesetz in aktueller Fassung). Die Herausgeber behalten sich deshalb das Recht vor Manuskripte abzulehnen die den o.g. Anforderungen nicht entsprechen. Der Autor haftet bei Verstoß gegen die o.g. Anforderungen oder bei falschen Angaben.

Current impact factor: 0.58

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 0.58
2013 Impact Factor 0.538
2012 Impact Factor 0.42
2011 Impact Factor 0.4
2010 Impact Factor 0.543
2009 Impact Factor 0.464
2008 Impact Factor 0.57
2007 Impact Factor 0.653
2006 Impact Factor 0.533
2005 Impact Factor 0.484
2004 Impact Factor 0.514
2003 Impact Factor 0.473
2002 Impact Factor 0.507
2001 Impact Factor 0.62
2000 Impact Factor 0.722
1999 Impact Factor 0.486
1998 Impact Factor 0.675
1997 Impact Factor 0.621

Impact factor over time

Impact factor

Additional details

5-year impact 0.51
Cited half-life 8.20
Immediacy index 0.19
Eigenfactor 0.00
Article influence 0.09
Website HNO website
Other titles HNO (Online), Hals- Nasen- Ohrenheilkunde
ISSN 1433-0458
OCLC 42964434
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Springer Verlag

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Author's pre-print on pre-print servers such as
    • Author's post-print on author's personal website immediately
    • Author's post-print on any open access repository after 12 months after publication
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany link to published version (see policy)
    • Articles in some journals can be made Open Access on payment of additional charge
  • Classification
    ​ green

Publications in this journal

  • HNO 09/2015; DOI:10.1007/s00106-015-0064-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Loss of voice is the consequence of laryngectomy most disturbing for the patient. As such, the notion of performing a laryngectomy has always been directly linked to the possibility of voice rehabilitation. The multitude of different technical and surgical approaches pays testimony to the problems associated with rehabilitation of speech and swallowing after laryngectomy. Methods: Scientific online search engines and library facilities were used to search for recent publications and historical medical documents. Important works were identified and summarized. Results: Four different categories of voice rehabilitation can be identified: external (electrical) devices, esophageal speech, and tracheoesophageal shunts either with or without fistula valves/voice prosthesis. During the past three decades, fistula valves/voice prostheses have become the state of the art, with some patients still using esophageal speech or external devices as a back-up method in case of prosthesis failure.
    HNO 09/2015; DOI:10.1007/s00106-015-0043-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the past three decades, the use of voice prostheses has developed worldwide into the gold standard for voice rehabilitation after total laryngectomy. Insertion of a voice prosthesis is a simple and rapid surgical procedure, which is associated with a low rate of complications. The current article describes the cases of 2 patients showing a rapid development of granulation tissue around the voice fistula, leading to complete incarceration of the prosthesis and subtotal/total stenosis of the neopharynx.
    HNO 09/2015; DOI:10.1007/s00106-015-0059-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Adaptive desensitization still remains the only causative therapy for acetylsalicylic acid (ASA) hypersensitivity and is carried out nearly worldwide. To date there are hardly any data available on disease development under current desensitization therapy and longitudinal data in particular are missing. Study design: Out of a large collective of patients with proven hypersensitivity to ASA, 194 patients with initiated desensitization treatment were observed for periods up to 5 years (average 32 months). Results: Patients with immediate reactions to systemic challenge tests revealed a response rate of 77 % after 12 months of therapy. In this period 12 % reached complete remission, 38 % showed a clear reduction in symptoms, 32 % reached partial remission, 13 % remained unchanged and 5 % suffered from disease progression. Conclusion: Adaptive desensitization therapy for hypersensitivity to ASA has been shown to be an effective causative therapy and chronic hyperplastic sinusitis as well as bronchial asthma could be improved. For the determination of maintenance dosages and required time periods more data are needed.
    HNO 09/2015; DOI:10.1007/s00106-015-0065-y
  • [Show abstract] [Hide abstract]
    ABSTRACT: Balloon dilatation is a promising new treatment for Eustachian tube dysfunction which is becoming more and more popular in Germany. There are a number of single publications and even meta-analyses on this topic, which demonstrate good results but also reveal the need for better studies. Initially tube dilatation was applied only in adults with tube dysfunctions but recently some centers even recommend it for children with long-lasting or frequently recurring middle ear effusion, which is resistant to conventional therapy. This article provides a critical appraisal based on the current literature and emphasizes the need for controlled studies. Due to the poor definition of tube dysfunctions it may be difficult to establish informative studies but in terms of evidence-based medicine there is need for a precise definition of indications and inclusion criteria. Most important is that such studies must include control groups, which has so far not been the case. Moreover, there should be a consensus about the criteria for defining success. Although all publications claim that balloon tuboplasty is a safe method, the question whether or not preoperative computed tomography (CT) scans are needed should be considered in each individual case. Nevertheless, balloon dilatation is a very promising method offering a new approach to the problem of Eustachian tube dysfunction.
    HNO 09/2015; DOI:10.1007/s00106-015-0047-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article presents the case of a patient with a submandibular cervical tumor initially suspected to be a large lymph node or glomus tumor. However, the diagnostic workup prior to taking a biopsy sample revealed an extracranial aneurysm of the internal carotid artery. In order to prevent a permanent neurologic deficit arising from thromboembolism, the aneurysm was excluded by resection and arterial continuity was restored. Extracranial aneurysms of the internal carotid artery are rare, but serious differential diagnoses of cervical nodes. It is of paramount importance that this differential diagnosis be considered before initiating invasive diagnostics of these tumors.
    HNO 09/2015; DOI:10.1007/s00106-015-0062-1
  • HNO 09/2015; DOI:10.1007/s00106-015-0041-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vaccinations are the most successful and cost-effective measures for prevention of infections. Important pathogens of respiratory tract infections (e. g. influenza viruses and pneumococci) can be effectively treated by vaccinations. The seasonal trivalent and recently now quadrivalent influenza vaccines include antigens from influenza A and B type viruses, which have to be modified annually oriented to the circulating strains. The effective protection by influenza vaccination varies considerably (too short protection time, mismatch); therefore, administration late in the year is the best approach (November/December). Two pneumococcal vaccines are recommended for adults: the over 30-year-old 23-valent polysaccharide vaccine (PPV23) and the 4-year-old 13-valent conjugate vaccine (PCV13). The immunological and clinical efficacy of PPV23 is controversially discussed; however, a moderate reduction of invasive pneumococcal infections is widely accepted. The PCV13 stimulates a T-cell response and has currently demonstrated its clinical efficacy in an impressive study (CAPiTA). The problem of PCV13 is the relatively limited coverage of only 47 % of the currently circulating invasive pneumococcal serotypes.
    HNO 09/2015; 12(2). DOI:10.1007/s00106-015-0058-x
  • HNO 09/2015; DOI:10.1007/s00106-015-0056-z
  • HNO 09/2015; DOI:10.1007/s00106-015-0060-3
  • HNO 08/2015; DOI:10.1007/s00106-015-0051-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Balloon dilation of the Eustachian tube has recently been introduced as a novel and minimally invasive method for treating chronic obstructive Eustachian tube dysfunction. For the first time worldwide, we assessed the role of this technique in a large cohort of children with Eustachian tube dysfunction that did not respond to other treatments and in whom a tumor could be ruled out as the cause. This study is a retrospective analysis. We retrospectively analyzed the medical records of 66 children (mean age 8.12 years, range 4-14 years) who underwent balloon dilation of the Eustachian tube using the Bielefeld balloon catheter. There were no complications during surgery. Clinical symptoms improved in more than 80 % of the patients. No patient reported a deterioration of symptoms. Of the participating parents, over 80 % were very satisfied or satisfied with the treatment outcome. Balloon dilation is a rapid, simple, and safe method for treatment of both adults and children with Eustachian tube dysfunction that does not respond to other treatments. Further studies, ideally multicenter studies, are required in order to optimize the definition of existing and potential new indications for this treatment approach, as well as to establish this treatment in the management of children with refractory chronic Eustachian tube dysfunction.
    HNO 08/2015; DOI:10.1007/s00106-015-0050-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: At the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015, results of current trials dealing with nonsurgical primary treatment of locally advanced head and neck cancer were presented. Regarding concomitant chemoradiotherapy (CRT), studies focused on the dosage and sequence of cisplatin administration are currently particularly featured. Amongst these, a study on dosage reduction in human papilloma virus (HPV)-positive patients was presented. Other investigations addressed substances as alternatives for cisplatin, particularly carboplatin and targeted therapeutic agents. The comparison of concomitant and sequential CRT (induction chemotherapy (ICT) prior to CRT) is still one of the main topics. In addition, studies modifying the ICT regimen or combining subsequent radiotherapy (RT) with the epidermal growth factor receptor (EGFR) antibody cetuximab were presented. A selection of the most important trials are summarized in this article.
    HNO 08/2015; DOI:10.1007/s00106-015-0053-2
  • HNO 08/2015; 63(9). DOI:10.1007/s00106-015-0049-y
  • [Show abstract] [Hide abstract]
    ABSTRACT: The past century saw rapid development of craniofacial prostheses. Particularly the challenging issue of surgical fixation was the subject of intensive research and development. During the past three decades, the principle of osseointegration has proven to provide a reliable method for epithesis fixation. The continuous technical development of implant systems has led to almost minimally invasive surgical techniques, with ever increasing stability of the implants. Osseointegrated implants are a proven and durable solution in the rehabilitation of the patient with a defect in the craniofacial region. Overall complication rates are low. The design and mechanics of the implants, as well as the artificial body of the epithesis itself, are topics of current medical-technical research by anaplastologists and surgeons. Finally, functional prostheses, such as the tracheostomy epithesis, deserve particular attention.
    HNO 08/2015; DOI:10.1007/s00106-015-0035-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral venous and dural sinuses thrombosis (CVT) is a relatively rare but very serious disease, because of the risk of mortality. Cardinal symptoms are usually severe sudden-onset localized headaches, which may or not be accompanied by focal or generalized neurological deficits or seizures. It is particularly important to consider CVT in the presence of underlying prothrombotic conditions (genetically predisposed or acquired defects of the coagulation system) or well-known risk factors (hormonal contraception, pregnancy, puerperium, smoker status). Based on clinical findings, diagnosis is established using neuroimaging (MRI and MR venography, CT and CT venography) and D-dimer measurement. In the case of early diagnosis and onset of antithrombotic treatment, the prognosis is good. Otherwise there is a high risk of irreversible neurological deficits or even mortality. In daily clinical routine, where many patients present with similar or unspecific symptoms-most of which are harmless-it is thus particularly important that CVT be considered in the differential diagnosis.
    HNO 08/2015; DOI:10.1007/s00106-015-0044-3
  • HNO 08/2015; DOI:10.1007/s00106-015-0040-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Spiradenocarcinomas are rare malignant tumors that originate from the sweat glands of the skin and demonstrate aggressive growth. We report the case of an 86-year-old female patient presenting with a growth on the forehead which had been apparent for 2 years. After surgical removal of the tumor, histological workup culminated in the diagnosis of a spiradenocarcinoma. Surgical margins were free of tumor on pathological examination. Metastasis was excluded by positron-emission tomography-computed tomography (PET-CT). Due to the advanced age of the patient and the absence of metastatic disease, no adjuvant therapy was performed. Six months postoperatively there is no evidence of relapse.
    HNO 08/2015; DOI:10.1007/s00106-015-0045-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resection margins of melanomas in the head and neck region often have to be adapted according anatomical circumstances. In the case of thicker primary tumors or after complete resection of locoregional lymph node metastases, adjuvant therapy with interferon-α can be performed; in some cases, adjuvant radiotherapy may also be indicated. In the case of inoperable lymph node or distant metastases, systemic treatment is required. Beside well-established mono- or polychemotherapy regimens, newer targeted therapies with BRAF inhibitors (vemurafenib, dabrafenib), mitogenic-activated protein kinase (MEK) inhibitors (trametinib, binimetinib, and cobimetinib), and kinase inhibitors (imatinib, sunitinib, nilotinib, dasatinib) are also available.
    HNO 07/2015; 63(8). DOI:10.1007/s00106-015-0034-5